BioSpace News Archive

Psychemedics Corporation, the world’s largest provider of hair testing for drugs of abuse, announced fourth quarter and full year financial results for the period ended December 31, 2022.

Mesoblast Limited announced that, as part of the ongoing review of the BLA for remestemcel-L in the treatment of children with SR-aGVHD, the United States Food and Drug Administration has scheduled a Pre-License Inspection of Mesoblast’s cell therapy manufacturing operations at Lonza Bioscience in Singapore.

Jacobio Pharma announced it has entered into a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA to evaluate the combination of Jacobio’s CD73 monoclonal antibody JAB-BX102 in combination with Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy, KEYTRUDA®.

CASI Pharmaceuticals, Inc. announced that the redomiciliation merger to redomicile the Company as a Cayman Islands company has been completed.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) will present detailed results from the Phase 3 GLOW trial evaluating first-line treatment with zolbetuximab.

Predictive Oncology Inc. (Nasdaq: POAI), Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today reported financial and operating results for the year ended December 31, 2022, and provided a corporate update.

Karuna Therapeutics, Inc. announced the pricing of an underwritten public offering of 2,479,391 shares of its common stock at a public offering price of $161.33 per share.

IntelGenx Technologies Corp. announces the closing of an offering by way of private placement to certain investors in the United States of convertible notes due March 1, 2027 for aggregate gross proceeds of approximately US$760,000.

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough (“RCC”), today reported its financial and operating results for the year ended December 31, 2022.

American Aires Inc. (CSE: WIFI) (the “Company” or “Aires”) is pleased to announce that it intends to complete a non-brokered private placement (the “Private Placement”) for gross proceeds of up to $2,500,000 through the issuance of up to 50,000,000 units (the “Units”) at a price of $0.05 per Unit.